Secondary iron overload
- PMID: 11722978
- DOI: 10.1182/asheducation-2001.1.47
Secondary iron overload
Abstract
Transfusion therapy for inherited anemias and acquired refractory anemias both improves the quality of life and prolongs survival. A consequence of chronic transfusion therapy is secondary iron overload, which adversely affects the function of the heart, the liver and other organs. This session will review the use of iron chelating agents in the management of transfusion-induced secondary iron overload. In Section I Dr. John Porter describes techniques for the administration of deferoxamine that exploit the pharmacokinetic properties of the drug and minimize potential toxic side effects. The experience with chelation therapy in patients with thalassemia and sickle cell disease will be reviewed and guidelines will be suggested for chelation therapy of chronically transfused adults with refractory anemias. In Section II Dr. Nancy Olivieri examines the clinical consequences of transfusion-induced secondary iron overload and suggests criteria useful in determining the optimal timing of the initiation of chelation therapy. Finally, Dr. Olivieri discusses the clinical trials evaluating orally administered iron chelators.
Similar articles
-
Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.Hematol Oncol Clin North Am. 2014 Aug;28(4):703-27, vi. doi: 10.1016/j.hoc.2014.04.004. Hematol Oncol Clin North Am. 2014. PMID: 25064709 Review.
-
The Role of Deferiprone in Iron Chelation.N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219. N Engl J Med. 2018. PMID: 30485781 Review. No abstract available.
-
Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).Transfus Sci. 2000 Dec;23(3):211-23. doi: 10.1016/s0955-3886(00)00089-8. Transfus Sci. 2000. PMID: 11099897 Review.
-
Consequences and management of iron overload in sickle cell disease.Hematology Am Soc Hematol Educ Program. 2013;2013:447-56. doi: 10.1182/asheducation-2013.1.447. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319218 Review.
-
Thalassemia.Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review.
Cited by
-
Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2*MRI.Front Med (Lausanne). 2022 Mar 21;9:865669. doi: 10.3389/fmed.2022.865669. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35386917 Free PMC article. Review.
-
Effect of iron chelators on methemoglobin and thrombin preconditioning.Transl Stroke Res. 2012 Dec;3(4):452-9. doi: 10.1007/s12975-012-0195-4. Transl Stroke Res. 2012. PMID: 23585819 Free PMC article.
-
Deferoxamine deconditioning increases neuronal vulnerability to hemoglobin.Exp Cell Res. 2020 May 1;390(1):111926. doi: 10.1016/j.yexcr.2020.111926. Epub 2020 Feb 26. Exp Cell Res. 2020. PMID: 32112801 Free PMC article.
-
Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.Int J Hematol. 2014 Sep;100(3):254-9. doi: 10.1007/s12185-014-1624-9. Epub 2014 Jul 2. Int J Hematol. 2014. PMID: 24986748
-
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Cochrane Database Syst Rev. 2013. PMID: 23963793 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
